Alcon price target raised to $112 from $108 at KeyBanc

KeyBanc analyst Brett Fishbin raised the firm’s price target on Alcon (ALC) to $112 from $108 on higher multiple, while keeping an Overweight rating on the shares. Last Thursday, Alcon hosted its 2025 Capital Markets Day, which the firm believes demonstrated an impressive balance between consistent innovation and durable double digits earnings growth. More specifically in Surgical, KeyBanc remains encouraged by the upcoming rollout of next-gen Equipment and Consumables; in Vision Care, Alcon is accelerating its pipeline in Ophthalmic Pharma – while maintaining a healthy cadence of new products in Contact Lenses; and its long-term outlook included a target of 12%-15% EPS growth, despite an uptick in R&D as a percentage of sales.